Esmo 2020 – double win complicates the gastric cancer picture
Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.
Esmo 2020 puts Opdivo and Cabometyx back in the game
Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co’s Keytruda plus Inlyta in first-line renal cancer.
Gilead’s cancer ambitions stretch to $21bn
As Immunomedics and Seattle both get backing from the big boys, antibody-drug conjugates finally come of age.
